Regeneron Pharmaceuticals Inc : Regeneron Announces FDA Acceptance of EYLEA® (aflibercept) Injection Supplemental Biologics License Application for Review for Diabetic Macular Edema Indication
(Source: 4-traders) … the profits from sales of EYLEA, except for Japan where Regeneron receives a …IgG1 and formulated as an iso-osmotic solution for intravitreal administration.